143 related articles for article (PubMed ID: 21266946)
41. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK
Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641
[TBL] [Abstract][Full Text] [Related]
42. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain.
Ramil E; Sánchez AJ; González-Pérez P; Rodríguez-Antigüedad A; Gómez-Lozano N; Ortiz P; Arroyo R; De las Heras V; Vilches C; García-Merino A
Mult Scler; 2010 Feb; 16(2):139-46. PubMed ID: 20007426
[TBL] [Abstract][Full Text] [Related]
43. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
[TBL] [Abstract][Full Text] [Related]
44. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Caroff SN; Davis VG; Miller DD; Davis SM; Rosenheck RA; McEvoy JP; Campbell EC; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
J Clin Psychiatry; 2011 Mar; 72(3):295-303. PubMed ID: 20816031
[TBL] [Abstract][Full Text] [Related]
45. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
Greenbaum L; Alkelai A; Rigbi A; Kohn Y; Lerer B
Mov Disord; 2010 Dec; 25(16):2809-17. PubMed ID: 20939080
[TBL] [Abstract][Full Text] [Related]
46. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
[TBL] [Abstract][Full Text] [Related]
47. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
Lanning RK; Zai CC; Müller DJ
Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
[TBL] [Abstract][Full Text] [Related]
48. Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophrenia.
Hsieh CJ; Chen YC; Lai MS; Hong CJ; Chien KL
Psychiatry Res; 2011 Jun; 188(1):175-6. PubMed ID: 21055833
[No Abstract] [Full Text] [Related]
49. The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder: A case-control association study.
Yang C; Nolte IM; Ma Y; An X; Bosker FJ; Li J
Mol Genet Genomic Med; 2021 Sep; 9(9):e1752. PubMed ID: 34355541
[TBL] [Abstract][Full Text] [Related]
50. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of
Boiko AS; Ivanova SA; Pozhidaev IV; Freidin MB; Osmanova DZ; Fedorenko OY; Semke AV; Bokhan NA; Wilffert B; Loonen AJM
World J Biol Psychiatry; 2020 Jan; 21(1):72-77. PubMed ID: 30623717
[No Abstract] [Full Text] [Related]
51. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
52. CNR1 variation modulates risk for drug and alcohol dependence.
Zuo L; Kranzler HR; Luo X; Covault J; Gelernter J
Biol Psychiatry; 2007 Sep; 62(6):616-26. PubMed ID: 17509535
[TBL] [Abstract][Full Text] [Related]
53. Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia.
Lai IC; Liao DL; Bai YM; Lin CC; Yu SC; Chen JY; Wang YC
Neuropsychobiology; 2002; 46(4):173-5. PubMed ID: 12566932
[TBL] [Abstract][Full Text] [Related]
54. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.
Zhang XY; Zhang WF; Zhou DF; Chen DC; Xiu MH; Wu HR; Haile CN; Kosten TA; Kosten TR
Biol Psychiatry; 2012 Oct; 72(8):700-6. PubMed ID: 22695185
[TBL] [Abstract][Full Text] [Related]
55. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.
Ivanova SA; Loonen AJ; Pechlivanoglou P; Freidin MB; Al Hadithy AF; Rudikov EV; Zhukova IA; Govorin NV; Sorokina VA; Fedorenko OY; Alifirova VM; Semke AV; Brouwers JR; Wilffert B
Transl Psychiatry; 2012 Jan; 2(1):e67. PubMed ID: 22832729
[TBL] [Abstract][Full Text] [Related]
56. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
Souza RP; Remington G; Meltzer HY; Lieberman JA; Kennedy JL; Wong AH
Int Clin Psychopharmacol; 2010 Sep; 25(5):264-9. PubMed ID: 20436352
[TBL] [Abstract][Full Text] [Related]
57. Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia.
Tao R; Li C; Jaffe AE; Shin JH; Deep-Soboslay A; Yamin R; Weinberger DR; Hyde TM; Kleinman JE
Transl Psychiatry; 2020 May; 10(1):158. PubMed ID: 32433545
[TBL] [Abstract][Full Text] [Related]
58. A common variation in the cannabinoid 1 receptor (CNR1) gene is associated with pre-eclampsia in the Central European population.
Bienertova-Vasku J; Bienert P; Dostalova Z; Chovanec J; Vasku A; Vasku V
Eur J Obstet Gynecol Reprod Biol; 2011 Mar; 155(1):19-22. PubMed ID: 21129839
[TBL] [Abstract][Full Text] [Related]
59. Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesian Chinese Han patients with schizophrenia.
Wang F; Fan H; Sun H; Yang F; Luo Y; Liu H; Kosten TR; Lu L; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):106-10. PubMed ID: 22227290
[TBL] [Abstract][Full Text] [Related]
60. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia.
Ivanova SA; Geers LM; Al Hadithy AF; Pechlivanoglou P; Semke AV; Vyalova NM; Rudikov EV; Fedorenko OY; Wilffert B; Bokhan NA; Brouwers JR; Loonen AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():172-7. PubMed ID: 24389397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
